Dr Joe Yeong’s main research focus is to understand and overcome the resistance of immunecheckpoint blockade immunotherapy. As an immuno-pathologist, his key vision is to bridge between immunologists and pathologists to better harness the advances of immunotherapy and further beyond. He is the pioneer in automation of quantitative multiplex immunohistochemistry, using clinical autostainers to study and quantitate tumour immune microenvironment in clinical samples, and has published > 70 papers in this field. His works on cancer immunology are included in multiple National Medical Research Council funded studies as well as pharmaceutical industry sponsored projects. He also served as a committee member in the World Immunotherapy Council, Society for Immunotherapy of Cancer (SITC) and is one of the organizers for its 2019 WIC Global Symposium in Washington D.C., USA. He is also a board member of SLAS Technology (Journal), Frontiers and Pathogens. He serves as a Secretary (Executive) in Singapore Society of Oncology – Cancer Immunotherapy Consortium, as well as Co-lead of Diagnostic/Education in SingHealth Duke-NUS Cell Therapy Center.

Main Appointment

Group Leader
Institute of Molecular and Cell Biology (IMCB, A*STAR, Singapore)
Department of Anatomical Pathology, Singapore General Hospital (SGH)

Research Focus

  • Immunopathology
  • Immune microenvironment
  • Cross-cancer types including breast, liver, lung, virus-driven such as NPC, etc.
  • Immunoprofiling for immunotherapy
  • Multiplex IHC (Spatial “proteomics”)
  • Spatial Transcriptomics
  • Immune-profiling
  • Clinical assay translation